Phaseline

Companies › Zhejiang Doer Biologics

Zhejiang Doer Biologics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology, Gastroenterology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DR10624 Injection–Phase 2MASLD–
DR30206
Monoclonal antibody targeting gastrointestinal cancer
–Phase 1Gastrointestinal Cancer; Solid TumorApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07024212DR10624 InjectionPhase 2MASLDGastroenterologyJun 2026
NCT07056777DR30206Phase 1Gastrointestinal CancerOncologyApr 2027
NCT06132828DR30206Phase 1Solid TumorOncologyJul 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Institut de Recherches Internationales Servier (I.R.I.S.) Hinova Pharmaceuticals Beijing Sungen Biomedical Technology HighField Biopharmaceuticals Onconic Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.